Immix Biopharma

Q2 FY2026 EarningsQ2 FY2026 performance was mixed compared to consensus: revenue of $0 remained in-line with expectations for this clinical-stage biopharmaceutical firm, while GAAP EPS of -$0.18 missed the -$0.17 consensus mean. Net loss widened to $11.56M vs. the $11.03M expected, driven by a sharp 159% YoY surge in G&A expenses to $7.1M. Despite the bottom-line miss, a successful $140.7M public offering in May significantly bolstered the balance sheet, providing a cash runway of $232.1M for Phase 3 trials.